The in vitro effects of interferon-gamma, interferon-alpha, and tumour-necrosis factor-alpha on erythroid burst-forming unit growth in patients with non-leukaemic myeloproliferative disorders-Reference-Cited by-同舟云学术

The in vitro effects of interferon-gamma, interferon-alpha, and tumour-necrosis factor-alpha on erythroid burst-forming unit growth in patients with non-leukaemic myeloproliferative disorders

Published:2009-04-24 Issue:5 Volume:50 Page:250-254
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:

Author:

Kanfer Edward J.,Price Cathy M.,Gordon Andrea A.,Barrett A. John

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.1993.tb00157.x/fullpdf

Reference37 articles.

1. Primary polycythaemia, essential thrombocythaemia and myelofibrosis - three facets of a single disease process;Adams;Acta Haematologica,1988

2. Polycythemia vera: stem cell and probable clonal origin of the disease;Adamson;N Engl J Med,1976

3. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis;Jacobson;Blood,1978

4. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell;Fialkow;Blood,1981

5. The application of X-chromosome gene probes to the diagnosis of myeloproliferative disease;Lucas;Br J Haematol,1989

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia;Blood;2022-05-12

2. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea;Blood;2019-09-12

3. The Rationale for Immunotherapy in Myeloproliferative Neoplasms;Current Hematologic Malignancy Reports;2019-06-21

4. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial;The Lancet Haematology;2017-04

5. Biological Rationale and Clinical Use of Interferon in the Classical BCR-ABL-Negative Myeloproliferative Neoplasms;Journal of Interferon & Cytokine Research;2013-04